Influenza Vaccine in HIV Study

University of Melbourne

Status: Completed

Conditions: Influenza, Human

Treatments: Biological: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)

Study type: Observational

Funder types: Other

Identifiers

NCT02632578

Kent001

1041832, 1042634, 1052979 (Other Grant/Funding Number)

AISRF08020 (Other Grant/Funding Number)

Details and patient eligibility

About

The aims of this study are:

1. to investigate if HIV infection alters the antibody responses to influenza and
2. to assess the ability of licensed influenza vaccine to induce functional non-neutralising antibodies in HIV-infected and HIV-uninfected subjects.

Enrollment: 57 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• HIV-1 positive by licensed diagnostic test (for HIV-positive group only)
• Planning to receive the seasonal influenza vaccine outside the study
• Provision of written informed consent

Exclusion criteria

• Previous allergy to influenza vaccination
• Pregnancy or planning to become pregnant
• Unwilling or unable to provide blood samples

Trial design

57 participants in 2 patient groups

HIV-positive

Treatment:

Biological: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)

HIV-negative

Treatment:

Biological: 2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)